Jim Simons
DAWN

Jim Simons’s Day One Biopharmaceuticals DAWN Stock Holding History

Jim Simons’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$27.8M Sell
1,296,984
-8,100
-0.6% -$114K 0.04% 524
2025
Q4 		$12.2M Buy
1,305,084
+399,608
+44% +$3.34M 0.02% 826
2025
Q3 		$6.38M Sell
905,476
-95,064
-10% -$654K 0.01% 1349
2025
Q2 		$6.5M Buy
1,000,540
+652,100
+187% +$4.49M 0.01% 1348
2025
Q1 		$2.76M Buy
348,440
+104,700
+43% +$1.13M ﹤0.01% 1793
2024
Q4 		$3.09M Buy
243,740
+148,900
+157% +$2.07M ﹤0.01% 1755
2024
Q3 		$1.32M Buy
94,840
+22,700
+31% +$324K ﹤0.01% 2282
2024
Q2 		$994K Buy
+72,140
New +$1.06M ﹤0.01% 2326
2023
Q3 		– Sell
-139,164
Closed -$1.66M – 3732
2023
Q2 		$1.66M Sell
139,164
-239,936
-63% -$3.13M ﹤0.01% 2119
2023
Q1 		$5.07M Buy
379,100
+231,674
+157% +$4.53M 0.01% 1468
2022
Q4 		$3.17M Buy
147,426
+49,526
+51% +$1.02M ﹤0.01% 1780
2022
Q3 		$1.96M Sell
97,900
-18,730
-16% -$398K ﹤0.01% 2023
2022
Q2 		$2.09M Buy
+116,630
New +$1.2M ﹤0.01% 2152

Other funds holding DAWN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 26.7% 1-Year Est. Return

Jim Simons's DAWN Position: Q1 2026 in Review

Jim Simons reduced its Day One Biopharmaceuticals (DAWN) stake by 0.62% in Q1 2026, selling an estimated $114K and leaving 1,296,984 shares worth $27.8M. The position accounts for 0.04% of the portfolio, ranked #524.

Jim Simons first reported a position in DAWN in Q2 2022 and has held it in 13 quarters since. 207 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

  • Jim Simons held 1,296,984 shares of Day One Biopharmaceuticals worth $27.8M as of Q1 2026.
  • Jim Simons sold 8,100 Day One Biopharmaceuticals shares in Q1 2026, an estimated $114K.
  • Day One Biopharmaceuticals made up 0.04% of Jim Simons's portfolio in Q1 2026, its #524 holding.
  • Jim Simons first reported a position in Day One Biopharmaceuticals in Q2 2022 and has held it in 13 quarters since.
  • 207 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.